Tufts Center for the Study of Drug Development reported a large financial uplift from Medable’s agentic AI clinical monitoring tool, quantifying improvements using expected net present value modeling. In oncology simulations, Tufts estimated eNPV gains of about $7.5 million for phase 2, $11.3 million for combined phase 2/3, and $21 million for phase 3. The analysis also estimated ROI multiples of roughly 64x in phase 2 and 82x in phase 3, attributing value to operational efficiencies such as fewer on-site monitoring visits, reduced travel, and faster enrollment and database lock timelines. Tufts said agentic AI can accelerate development by about 18 weeks overall in its modeling. The report may influence how sponsors evaluate AI tooling for site operations and trial management, especially as CRO workflows increasingly rely on automation to compress timelines.